XTL Biopharmaceutica is trading at 6.70 as of the 22nd of November 2024, a 3.08 percent increase since the beginning of the trading day. The stock's open price was 6.5. XTL Biopharmaceutica has more than 65 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for XTL Biopharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of December 2022 and ending today, the 22nd of November 2024. Click here to learn more.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel. The company has 514.21 M outstanding shares. More on XTL Biopharmaceuticals
Although XTL Biopharmaceutica's alpha and beta are two of the key measurements used to evaluate XTL Biopharmaceutica's performance over the market, the standard measures of volatility play an important role as well.
Our tools can tell you how much better you can do entering a position in XTL Biopharmaceutica without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Content Syndication Now
Content Syndication
Quickly integrate customizable finance content to your own investment portal
XTL Biopharmaceutica financial ratios help investors to determine whether XTL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTL with respect to the benefits of owning XTL Biopharmaceutica security.